Publication: 2681

Publication: 2681

A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

URL

Google Scholar

Citation:: J Clin Oncol vol 35 (15 suppl) abstr 7503

Meeting Instance:: ASCO 2017
Year:: 2017
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes

Parents:: None
Children:: 2767

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:: Celegene
Grants:: U10CA180820, U10CA180821, U10CA180882, U10CA180828, U10CA180888, NCTN CA180863, CCSRI 021039

Corr. Author:
Authors:: Amy S. Ruppert John C. Byrd Nyla A. Heerema Mitchell Smith John Godwin Stephen Couban Todd A. Fehniger Michael Thirman Alese E. Halvorson Bercedis L. Peterson Martin S. Tallman Frederick R. Appelbaum Richard M. Stone Sue Robinson Julie E. Chang Sumithra J. Mandrekar Richard A. Larson

Networks:: LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007, LAPS-WI020, OH070, PCRC

Study: CALGB-10404
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: